连接大脑中的粉样蛋白负担的基因组和蛋白质组签名
Raquel Puerta1,2, Itziar de Rojas1,3, Pablo García-González1,3
1Ace Alzheimer Center Barcelona - Universitat Internacional de Catalunya, Spain.
medRxiv : the preprint server for health sciences
|September 16, 2024
概括
这项研究将粉样蛋白生物标记物的全基因组关联研究 (GWAS) 与蛋白质组数据相结合,以确定阿尔茨海默病 (AD) 的遗传因素. 研究人员发现了与粉样蛋白负担相关的APOE和GADL1位点,为AD的复杂遗传结构提供了洞察力.
科学领域:
- 神经遗传学 神经遗传学
- 复杂疾病遗传学 复杂疾病遗传学
- 生物标志物发现发现
背景情况:
- 阿尔茨海默病 (AD) 具有显著的遗传性,但许多遗传风险因素仍未确定.
- 粉样蛋白病理,阿尔茨海默病的一个标志,可以使用脑脊液 (CSF) 和正子发射断层扫描 (PET) 生物标志物进行评估.
研究的目的:
- 通过分析粉样内类型来识别阿尔茨海默病的新型遗传风险因素.
- 通过综合遗传和蛋白质组学分析,研究AD中粉样蛋白病理背后的生物学途径.
主要方法:
- 在多个队伍中对CSF Aβ42和PET测量进行全基因组关联研究 (GWAS) 的元分析.
- 计算的多基因风险评分 (PRS) 针对阿尔茨海默病状态和粉样体内基因表型.
- 集成的GWAS结果与CSF蛋白质组数据 (SOMAscan) 并与大型公共数据集进行了比较.
主要成果:
- 确定了rs429358-APOE位点的全基因组显著性和GADL1位点的暗示性显著性.
- 在AD多基因风险得分和粉样蛋白水平之间发现了显著的关联.
- 发现了1387个与CSF Aβ42水平相关的FDR显著蛋白质,GWAS位点和蛋白质之间存在有限的重叠.
结论:
- 关于粉样内类型和CSF蛋白质组分析的GWAS的综合方法对于识别AD相关信号是有效的.
- 丰富分析揭示了信号通路,将粉样化与突触功能和精神障碍联系起来.
- 这一策略有助于阐明推动阿尔茨海默病中粉样蛋白调动的分子机制.
相关概念视频
Amyloid Fibrils
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid Fibrils
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...


